Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTEG- Bloodless Glucose Monitor -- Ignore unavailable to you. Want to Upgrade?

To: DryHeat who wrote (164)	8/16/1998 10:37:00 PM
From: Tevyah	Read Replies (2) \| Respond to of 176

I'm no financial guru, but is Integ going to be a great buy tomorrow am? From fridays financials: Shareholder equity/Nbr of shares = 17,392K/9462K = $1.84 share, not including the value of their collection technology and patents. Certainly they have made a painful decision and seem to be already proceeding with plan B. Somehow I believe this will be ok in the long run. Ken

To: DryHeat who wrote (164)	8/17/1998 8:00:00 AM
From: beach3	Respond to of 176

Integ Reports 1998 Second Quarter Results ST. PAUL, Minn., Aug. 14 /PRNewswire/ -- Integ Incorporated (Nasdaq: NTEG - news) today reported a net loss for the second quarter ended June 30, 1998, of $3.3 million, or $0.35 per share, compared to a net loss of $2.5 million, or $0.27 per share, for the second quarter of 1997. As a development stage company, Integ does not yet have revenues. Integ Incorporated is developing the LifeGuide System, a hand-held glucose monitoring product for use by people with diabetes. The LifeGuide System will allow people with diabetes to frequently self-monitor their glucose levels using interstitial fluid (ISF), the clear fluid found between cells throughout the body, without repeatedly enduring the pain of lancing their fingers and the need to draw blood. Frequent monitoring will allow people with diabetes to manage their disease more effectively and conveniently. ''During the second quarter, we completed our large scale internal study that tested our LifeGuide System on more than 450 people with diabetes,'' said Susan L. Critzer, Integ vice president, operations and interim president. ''The study has allowed us to draw definitive conclusions regarding the LifeGuide System performance and the steps required to bring our painless and bloodless technology to the market as quickly as possible''. According to Critzer, the study results: Confirmed on a large patient population that the glucose concentration present in ISF is clinically equivalent to the glucose concentration in venous blood. Demonstrated that Integ's proprietary sampling technology can reliably collect and deliver a one microliter sample of ISF fluid, a quantity sufficient for accurate measurement by multiple currently available technologies. Showed that the Company's infrared technology for measuring glucose levels in ISF requires additional improvements to achieve clinically acceptable performance. ''Based on the study results, we have concluded that the shortest path to a small, lightweight commercial LifeGuide System is to incorporate a proven measurement technology, such as strips or biosensors. We are currently exploring various options, including evaluating potential corporate alliances that could expedite this integration. As part of our ongoing R&D efforts, we have demonstrated the near-term feasibility of integrating either electrochemical or colorimetric measurement technology with Integ's patented ISF sample collection technique. Integ holds U.S. patents which provide coverage on ISF sampling across a range of measurement technologies. During the quarter Integ received notice of allowance on an additional U.S. patent that significantly broadens the Company's proprietary rights covering ISF collection techniques. Additional patent applications are pending. ''The Board of Directors believes that decisions flowing from the large- scale study will enable Integ to develop a predicable work plan to achieve commercialization of Integ's breakthrough product,'' said Mark B. Knudson, Ph.D., Integ chairman. ''Our cash reserves are adequate to pursue product development with a new measurement technology. The Company is in excellent hands with the current management team. These decisions could influence the CEO search we announced in January.'' Certain statements in this press release constitute ''forward looking statements'' as defined in the Private Securities Litigation Reform Act of 1995. All forward looking statements involve risks and uncertainties that may cause the Company's actual results to be materially different. Factors that could impact the Company's future results are described in the Company's Cautionary Statement, Exhibit 99.1 of the Company's 1997 Annual Report on Form 10-K and the 1998 Quarterly Report on Form 10-Q.